We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Zynerba Pharmaceuticals Inc | NASDAQ:ZYNE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.30 | 1.30 | 1.24 | 0 | 01:00:00 |
| | | | | 1 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 8 | | | |
| | | | | 21 | | | |
| | | | | 23 | | | |
| | | | | 29 | | | |
| | | | | 30 | | | |
| | | | | 30 | | | |
| | | | | 31 | | | |
| | | | | 33 | | | |
| | | | | 33 | | | |
| | | | | 34 | | | |
| | | | | 35 | | | |
| | | | | 37 | | | |
| | | | | 38 | | | |
| | | | | 39 | | | |
| | | | | 39 | | | |
| | | | | 39 | | | |
| | | | | A-1 | | |
|
Date:
|
| | June 9, 2021 | |
|
Time:
|
| | 10:00 a.m. Eastern Time | |
|
Location:
|
| | The meeting can be accessed by visiting https://web.lumiagm.com/236626312 (password: zyne2021), where you will be able to attend the meeting live via webcast, submit questions and vote online. There will be no physical location for stockholders to attend. | |
|
Record Date:
|
| | April 14, 2021 | |
|
Number of Common Shares Eligible to Vote as of the Record Date:
|
| | 41,251,537 | |
| | | | | | |
Board Recommendation
|
| |
Page Reference
(for more detail) |
|
|
Proposal 1:
|
| | Elect Seven Directors | | |
☒
FOR EACH NOMINEE
|
| | | |
|
Proposal 2:
|
| | Ratify the appointment of KPMG LLP as Independent Registered Public Accounting Firm for the 2021 Fiscal Year | | |
☒
FOR
|
| | | |
|
Proposal 3:
|
| | Approve and adopt an amendment to our Sixth Amended and Restated Certificate of Incorporation to make the federal district courts of the United States of America the exclusive forum for certain legal actions | | |
☒
FOR
|
| | | |
|
Proposal 4:
|
| | Approve, on an advisory basis, the compensation of our named executive officers | | |
☒
FOR
|
| | | |
|
Proposal 5:
|
| | Indicate, on an advisory basis, the preferred frequency with which future advisory votes on the compensation of our named executive officers should be held | | |
☒
FOR ONE YEAR
|
| | |
| | | | | | | | | | | |
Committee Membership
|
| ||||||
Name
|
| |
Age
|
| |
Director
Since |
| |
Principal Occupation
|
| |
AC
|
| |
CC
|
| |
NCGC
|
|
Armando Anido | | |
63
|
| |
2014
|
| | Chairman & Chief Executive Officer of Zynerba Pharmaceuticals, Inc. | | | | | | | | | | |
John Butler
|
| |
56
|
| |
2018
|
| |
President and Chief Executive Officer of Akebia Therapeutics, Inc.
|
| | | | |
|
| |
|
|
Warren D. Cooper, MB, BS, BSc, MFPM†
|
| |
68
|
| |
2015
|
| |
Partner & Chief Medical Officer of Healthcare Royalty Partners
|
| |
|
| | | | |
|
|
William J. Federici
|
| |
61
|
| |
2015
|
| |
Retired Senior Vice President and Chief Financial Officer of West Pharmaceutical Services, Inc.
|
| |
|
| | | | | | |
Daniel L. Kisner, MD
|
| |
74
|
| |
2015
|
| |
Independent Consultant
|
| | | | |
|
| | | |
Kenneth I. Moch
|
| |
66
|
| |
2015
|
| |
Independent Consultant
|
| |
|
| |
|
| | | |
Pamela Stephenson
|
| |
53
|
| |
2019
|
| |
Chief Commercial Officer of Albireo Pharma, Inc.
|
| | | | | | | |
|
|
| Size of Board (set by the Board) | | | 7 | |
| Number of Independent Directors | | | 6 | |
| Lead Independent Director | | | Yes | |
| Board Self-Evaluation | | | Annual | |
| Review of Independence of Board | | | Annual | |
| Independent Directors Meet Without Management Present | | | Yes | |
| Annual Director Elections | | | Yes | |
| Voting Standard for Election of Directors in Uncontested Elections | | | Plurality | |
| Diversity of Board background, experience and skills | | | Yes | |
Proposal
|
| |
Votes Required
|
| |
Treatment of Abstentions and
Broker Non-Votes |
| |
Broker
Discretionary Voting |
|
Proposal 1 – Election of Seven Directors | | | Plurality of votes cast | | | Abstentions and broker non-votes will not be taken into account in determining the outcome of the proposal | | |
No
|
|
Proposal 2 – Ratification of Appointment of KPMG LLP as our Independent Registered Public Accounting Firm for the 2021 Fiscal Year | | | Majority of shares present and entitled to vote on the proposal in person (virtually) or represented by proxy | | | Abstentions and broker non-votes will have the effect of negative votes. | | |
Yes
|
|
Proposal 3 – To approve and adopt an amendment to our Sixth Amended and Restated Certificate of Incorporation to make the federal district courts of the United States of America the exclusive forum for certain legal actions. | | | Majority of the shares of common stock issued and outstanding as of the record date | | | Abstentions and broker non-votes will have the same effect as a negative vote. | | |
No
|
|
Proposal 4 – To approve, on an advisory basis, the compensation of our named executive officers. | | | Majority of shares present and entitled to vote on the proposal in person (virtually) or represented by proxy | | | Abstentions and votes withheld will have the same effect as a negative vote. Broker non-votes will not be taken into account in determining the outcome of the proposal. | | |
No
|
|
Proposal 5 – Advisory vote on the preferred frequency with which future advisory votes on the compensation of our named executive officers should be held. | | | The option of one year, two years or three years that receives the highest number of votes cast by the holders of shares present in person or by proxy at the meeting, and entitled to vote, will be considered by the Board as the frequency preferred by the stockholders. | | | N/A. | | |
No
|
|
|
|
| |
|
| |
|
|
|
Mailing your signed proxy card or voter instruction card.
|
| |
Using the Internet at www.voteproxy.com.
|
| |
Calling toll-free from the United States, U.S. territories and Canada to 1-800-776-9437.
|
|
| | | | | | | | |
Committee Membership
|
| ||||||
Name, Age
|
| |
Age
|
| |
Position
|
| |
AC
|
| |
CC
|
| |
NCGC
|
|
Armando Anido | | |
63
|
| | Chairman of the Board and CEO | | | | | | | | | | |
Terri B. Sebree | | |
63
|
| | President | | | | | | | | | | |
James E. Fickenscher | | |
57
|
| | CFO and VP, Corporate Development | | | | | | | | | | |
Suzanne M. Hanlon | | |
64
|
| |
Secretary, VP and General Counsel
|
| | | | | | | | | |
Brian Rosenberger | | |
52
|
| | VP, Commercial and Business Development | | | | | | | | | | |
John P. Butler
|
| |
56
|
| |
Director
|
| | | | |
|
| |
|
|
Warren D. Cooper, MB, BS, BSc, MFPM†
|
| |
68
|
| |
Director
|
| |
|
| | | | |
|
|
William J. Federici
|
| |
61
|
| |
Director
|
| |
|
| | | | | | |
Daniel L. Kisner, MD
|
| |
74
|
| |
Director
|
| | | | |
|
| | | |
Kenneth I. Moch
|
| |
66
|
| |
Director
|
| |
|
| |
|
| | | |
Pamela Stephenson
|
| |
53
|
| |
Director
|
| | | | | | | |
|
|
| Armando Anido | | ||||||
|
Age: 63
Chairman and Chief Executive Officer Since: 2014 |
| |
Committee Memberships: N/A
|
| | Other Public Directorships: Auris Medical Holding Ltd.; SCYNEXIS, Inc. | |
| Armando Anido has served as chairman of our Board and as our chief executive officer since October 2014. Prior to joining our company, Mr. Anido served as our business consultant from May 2014 to October 2014. Mr. Anido has more than 40 years of executive, operational and commercial leadership experience in the pharmaceutical industry. Mr. Anido served as chief executive officer and as a director of NuPathe, Inc. (“NuPathe”), a publicly-traded specialty pharmaceutical company, from July 2012 through March 2014, during which time he led the company through U.S. Food and Drug Administration (“FDA”) approval of its lead product Zecuity®, a transdermal patch for migraines. Prior to joining NuPathe, Mr. Anido served as chief executive officer and president and as a director of Auxilium Pharmaceuticals, Inc. (“Auxilium”), a specialty pharmaceutical company, from July 2006 through December 2011, where he led the company in its commercialization of its lead product, Testim®, a testosterone gel. Additionally, Mr. Anido led the company through the FDA approval and commercialization of Xiaflex®, an injectable collagenase for Dupuytren’s Contracture. Mr. Anido currently serves as a director of Auris Medical, a pharmaceutical company, and has held such position since April 2016, and as a director of Scynexis, Inc. a pharmaceutical company, and has held such position since January 2019. He formerly served as a director of Aviragen Therapeutics, a pharmaceutical company, from October 2015 to March 2018, Respira Therapeutics, Inc., a pharmaceutical company, from May 2012 through September 2014, and Adolor Corporation, a pharmaceutical company, from September 2003 through December 2011. Mr. Anido holds a B.S. in Pharmacy and an MBA, both from West Virginia University. | | ||||||
| Skills and Qualifications: With more than 40 years of experience in the pharmaceutical industry, Mr. Anido brings valuable executive, operational and commercial expertise to our Board. | |
| Terri B. Sebree | | ||||||
|
Age: 63
Officer Since: 2014 |
| | | | |
Other Public Directorships: None
|
|
| Terri B. Sebree has served as our president since October 2014, and served as our treasurer from October 2014 to December 2014. Prior to joining our company, Ms. Sebree served as our business consultant from May 2014 to October 2014. Ms. Sebree has more than 35 years of executive, development and operational experience in the pharmaceutical industry, particularly in central nervous system product development including epilepsy and pain. Ms. Sebree founded and served as president of NuPathe, a specialty pharmaceutical company, from February 2005 until April 2014, where she led the effort to develop, achieve regulatory approval for and complete manufacturing of the company’s lead product, Zecuity, a transdermal patch for migraines. Prior to founding NuPathe, Ms. Sebree served as senior vice president, development of Auxilium, a specialty pharmaceutical company, where she led the development and approval program of Testim, a testosterone gel. Prior to joining Auxilium, Ms. Sebree served as executive vice president, U.S. Operations at IBAH, Inc., a contract research organization. Prior to that, Ms. Sebree served in a variety of management roles with Abbott Laboratories Inc., a global healthcare company, for over nine years. Ms. Sebree currently serves on the board of directors of Serodus ASA, a private Scandinavian pharmaceutical company. Ms. Sebree holds a B.S. from Texas A&M University. | |
| James E. Fickenscher | | ||||||
|
Age: 57
Officer Since: 2016 |
| | | | |
Other Public Directorships: None
|
|
| James E. Fickenscher has served as our chief financial officer, vice president corporate development since September 2016. Mr. Fickenscher has more than 30 years of financial, business development and executive leadership experience in the pharmaceutical industry. Prior to joining our company, he served as the senior vice president, chief financial officer of Antares Pharma, Inc., a specialty pharmaceutical company, from November 2014 to September 2016. Previously, Mr. Fickenscher served as chief financial officer of Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, from May 2005 until August 2014. From January 2000 until April 2004, Mr. Fickenscher served as senior vice president chief financial officer of Aventis Behring L.L.C., a wholly owned subsidiary of Aventis, predecessor to Sanofi S.A. Mr. Fickenscher joined Aventis Behring L.L.C. in 1995 as vice president, business development and strategic planning and, from that time until 2000, also held the positions of general manager, Japan and vice president & general manager, Hemophilia Business Unit. Throughout his tenure at Aventis Behring L.L.C, he was also responsible for strategic planning. Prior to Aventis Behring L.L.C., Mr. Fickenscher worked at Rhone-Poulenc Rorer, predecessor to Sanofi S.A., in its Collegeville, PA and Paris, France offices and at Deloitte & Touche LLP. Mr. Fickenscher received his B.S. at Bloomsburg University of Pennsylvania. He is a member of the American Institute of Certified Public Accountants. | |
| Suzanne M. Hanlon | | ||||||
|
Age: 64
Officer Since: 2014 |
| | | | |
Other Public Directorships: None
|
|
| Suzanne M. Hanlon has served as our secretary, vice president and general counsel since October 2014. Prior to joining our company, Ms. Hanlon served as our legal consultant from May 2014 to October 2014. Ms. Hanlon has more than 25 years of legal experience in the pharmaceutical industry. Ms. Hanlon served as vice president, associate general counsel of NuPathe from July 2005 to April 2014, where she worked with Mr. Anido and Ms. Sebree on the regulatory approval of Zecuity, a transdermal patch for migraines. Prior to joining NuPathe, Ms. Hanlon served as chief development counsel of Auxilium, a specialty pharmaceutical company. Prior to joining Auxilium, Ms. Hanlon served as vice president of global contracts and general counsel at IBAH, Inc. Prior to joining IBAH, Inc., Ms. Hanlon was a partner at Montgomery McCracken Walker & Rhoads LLP. Ms. Hanlon holds a B.A. from Pennsylvania State University and a J.D. from Villanova University School of Law. | |
| Brian Rosenberger | | ||||||
|
Age: 52
Officer Since: 2017 |
| | | | |
Other Public Directorships: None
|
|
| Brian Rosenberger has served as our vice president, commercial and business development, since January 2017. Over his career in the pharmaceutical industry, Mr. Rosenberger has held several leadership roles in marketing, sales, business development analytics and alliance management. Prior to joining our company, he was vice president, alliance & strategic portfolio management at Cipher Pharmaceuticals, a publicly-traded, Canadian-based dermatology company, from May 2015 to January 2017, where he managed the company’s global portfolio. From 2008 to April 2015, Mr. Rosenberger also held various roles of increasing responsibility at Auxilium Pharmaceuticals, a specialty biopharmaceutical company. In his last role as executive director, corporate development & licensing and alliance management he participated in several transformational M&A, licensing and co-promotion deals through and including Endo International’s acquisition of Auxilium in January 2015. Prior to joining Auxilium, Mr. Rosenberger held sales managerial positions at Neurocrine Biosciences during the initial commercial build-out of the organization and spent over a decade at GlaxoSmithKline in various U.S. and global commercial roles within specialty markets, including neurohealth epilepsy marketing. Mr. Rosenberger received a B.A. double major in Political Science/Policy and Management Studies from Dickinson College in Carlisle, PA. | |
| Warren D. Cooper, MB, BS, BSc, MFPM | | ||||||
|
Age: 68
Board Member Since: 2015 |
| | Committee Memberships: Audit Committee, Member; Nominating and Corporate Governance Committee, Member | | |
Other Public Directorships: None
|
|
| Warren D. Cooper, MB, BS, BSc, MFPM has served as a member of our Board since August 2015. Dr. Cooper is a U.K.-trained physician with more than 40 years of experience in the global pharmaceutical industry. Since January 2017, Dr. Cooper has served as chief medical officer and a partner of Healthcare Royalty Partners, a healthcare investment firm. Prior to joining Healthcare Royalty Partners in January 2017, Dr. Cooper served as the president of Coalescence Inc., a healthcare and pharmaceutical development consultancy, where he held various positions since 1999. Dr. Cooper was the chief executive officer of Prism Pharmaceuticals, Inc., a venture-backed, specialty pharmaceutical company that he led from inception in September 2004 until the sale of the company to Baxter International in May 2011. His career in the pharmaceutical industry began with Merck, Sharp and Dohme and spanned 12 years, initially as a clinical research physician in the United Kingdom, then as head of European and, subsequently, Worldwide Clinical Research Operations for Merck Research Laboratories across all therapeutic areas. Moving to AstraMerck (now AstraZeneca PLC, or “AstraZeneca”), in a broad clinical development role, he eventually led that company’s cardiovascular business division, a role with full business lifecycle leadership from in-licensing through development, to P&L responsibility for sales and marketing. Dr. Cooper is a member of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom. He has previously served on the boards of directors of Nutrition 21, Inc., Nuron Biotech Inc., Cardiorentis AG and the World Affairs Council of Philadelphia. Dr. Cooper holds a B.Sc. in Physiology, an M.B. and a B.S., each from the London Hospital, University of London. | | ||||||
| Skills and Qualifications: With more than 40 years of experience in the global pharmaceutical industry, Dr. Cooper brings valuable expertise in pharmaceutical company leadership and clinical pharmaceutical research to our Board. | |
| William J. Federici | | ||||||
|
Age: 61
Board Member Since: 2015 |
| | Committee Memberships: Audit Committee, Chair | | |
Other Public Directorships: None
|
|
| William J. Federici has served as a member of our Board since August 2015. Mr. Federici served as senior vice president and chief financial officer of West Pharmaceutical Services, Inc., a publicly traded global pharmaceutical technology company, from August 2003 until June 2018. He served as a member of the board of directors and chairman of the Audit committee at NuPathe from January 2011 until February 2014. From June 2002 until August 2003, he was national industry director for Pharmaceuticals of KPMG LLP, and prior thereto, he was an audit partner with Arthur Andersen, LLP. Mr. Federici holds a B.A. in Economics and an M.B.A. in Professional Accounting from Rutgers University and is a Certified Public Accountant. | | ||||||
| Skills and Qualifications: With his leadership experience in the global pharmaceutical and accounting industries, Mr. Federici brings valuable expertise in financial and audit-related matters to our Board. | |
| Pamela Stephenson | | ||||||
|
Age: 53
Board Member Since: 2019 |
| | Committee Memberships: Nominating and Corporate Governance Committee, Chair | | |
Other Public Directorships: None
|
|
| Pamela Stephenson was appointed as a member of our Board of Directors in February 2019. Ms. Stephenson has more than 20 years of experience leading the development and implementation of pharmaceutical marketing plans. Since March 2019, Ms. Stephenson has served as chief commercial officer for Albireo Pharma, Inc., a publicly traded biopharmaceutical company. Prior to that, she served as a vice president at Vertex Pharmaceuticals, Inc. (“Vertex”), a publicly traded global biotechnology company, from July 2008 to March 2019, where she was responsible for leading the global market access and pricing strategy for current and future products. Earlier in her tenure at Vertex, Ms. Stephenson led marketing and sales activities for the company’s hepatitis C and cystic fibrosis lines of business, and oversaw the U.S. launches of Incivek® (telaprevir) and Orkambi® (lumacaftor/ivacaftor). Prior to Vertex, Ms. Stephenson held roles of increasing strategic importance at Pfizer Inc., a publicly traded global pharmaceutical company, from October 1998 to June 2008. Ms. Stephenson received her B.A. from Brown University and M.P.H. from the Boston University School of Public Health. | | ||||||
| Skills and Qualifications: With her extensive experience in the commercialization and marketing of pharmaceutical products, including for the treatment of rare and near rare diseases, Ms. Stephenson brings valuable expertise in commercial planning, market development, product launch and market access to our Board. | |
|
Director Skills and Experience
|
| ||||||||||||||||||||||||||||||||||||||||||
| | | |
Anido
|
| |
Butler
|
| |
Cooper
|
| |
Federici
|
| |
Kisner
|
| |
Moch
|
| |
Stephenson
|
| |||||||||||||||||||||
|
Pharmaceutical Industry
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Executive Leadership
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Finance & Accounting
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Corporate Governance
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Executive Compensation
|
| | |
|
✓
|
| | | |
|
✓
|
| | | | | | | | | | | | | | | |
|
✓
|
| | | |
|
✓
|
| | | | | | | |
|
Regulatory Risk Management
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Commercialization/Sales & Marketing
|
| | |
|
✓
|
| | | |
|
✓
|
| | | | | | | | | | | | | | | |
|
✓
|
| | | |
|
✓
|
| | | |||||
|
Corporate Strategy & Business Development
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
|
Partnering/Mergers & Acquisitions
|
| | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| | | |
|
✓
|
| |
Name of Non-Employee Director
|
| |
Fee Earned or
Paid in Cash ($) |
| |
Option
Awards ($)(1) |
| |
Total ($)
|
| |||||||||
Warren D. Cooper, MB, BS, BSc, MFPM(2)
|
| | | | 66,500 | | | | | | 52,048 | | | | | | 118,548 | | |
John P. Butler(2)
|
| | | | 45,000 | | | | | | 52,048 | | | | | | 97,048 | | |
William J. Federici(2)
|
| | | | 55,000 | | | | | | 52,048 | | | | | | 107,048 | | |
Daniel L. Kisner, M.D.(2)
|
| | | | 47,500 | | | | | | 52,048 | | | | | | 99,548 | | |
Kenneth I. Moch(2)
|
| | | | 48,500 | | | | | | 52,048 | | | | | | 100,548 | | |
Pamela Stephenson(2)
|
| | | | 43,000 | | | | | | 52,048 | | | | | | 95,048 | | |
Position
|
| |
Additional Cash
Retainer in 2020 ($) |
| |
Additional Cash
Retainer in 2021 ($) |
| ||||||
Audit Committee | | | | | | | | | | | | | |
Chair
|
| | | | 20,000 | | | | | | 20,000 | | |
Member
|
| | | | 7,500 | | | | | | 10,000 | | |
Compensation Committee | | | | | | | | | | | | | |
Chair
|
| | | | 12,500 | | | | | | 15,000 | | |
Member
|
| | | | 6,000 | | | | | | 7,000 | | |
Nominating and Corporate Governance Committee | | | | | | | | | | | | | |
Chair
|
| | | | 8,000 | | | | | | 10,000 | | |
Member
|
| | | | 4,000 | | | | | | 5,000 | | |
Name and Principal Position
|
| |
Year
|
| |
Salary ($)
|
| |
Non-equity
incentive plan compensation ($)(1) |
| |
Stock
Awards ($)(2) |
| |
Option
Awards ($)(3) |
| |
All Other
Compensation ($)(4) |
| |
Total ($)
|
| |||||||||||||||||||||
Armando Anido
|
| | | | 2020 | | | | | | 585,265 | | | | | | 263,369 | | | | | | — | | | | | | 580,674 | | | | | | 53,441 | | | | | | 1,482,749 | | |
Chairman of the Board and CEO
|
| | | | 2019 | | | | | | 568,218 | | | | | | 334,112 | | | | | | — | | | | | | 413,149 | | | | | | 54,092 | | | | | | 1,369,571 | | |
Terri B. Sebree
|
| | | | 2020 | | | | | | 450,883 | | | | | | 209,660 | | | | | | — | | | | | | 428,858 | | | | | | 26,251 | | | | | | 1,115,652 | | |
President
|
| | | | 2019 | | | | | | 437,750 | | | | | | 252,144 | | | | | | 13,140 | | | | | | 309,861 | | | | | | 25,985 | | | | | | 1,038,880 | | |
James E.
Fickenscher |
| | | | 2020 | | | | | | 409,932 | | | | | | 129,129 | | | | | | — | | | | | | 303,775 | | | | | | 43,763 | | | | | | 886,599 | | |
CFO and VP, Corporate Development
|
| | | | 2019 | | | | | | 390,411 | | | | | | 158,347 | | | | | | — | | | | | | 227,487 | | | | | | 47,862 | | | | | | 824,107 | | |
| Abeona Therapeutics | | | Cara Therapeutics, Inc. | | | Glycomimetics, Inc. | |
| Achillion | | | Catabasis Pharmaceuticals, Inc. | | | Immunogen | |
| Adamas Pharmaceuticals, Inc | | | ChemoCentryx, Inc. | | | Inovio | |
| Akebia Therapeutics, Inc. | | | Chiasma, Inc. | | | Medicinova Inc. | |
| Ardelyx, Inc | | | Concert Pharmaceuticals, Inc. | | | Minerva Neurosciences, Inc. | |
| Assembly Biosciences, Inc | | | Corbus Pharmaceuticals, Inc. | | | Ovid Therapeutics | |
| Athersys, Inc. | | | Cytokinetics | | | Trevena | |
| Biocryst Pharmaceuticals, Inc. | | | Galectin Therapeutics, Inc. | | | | |
| Abeona Therapeutics | | | Chiasma, Inc. | | | Ocular Therapeutics, Inc. | |
| Adamas Pharmaceuticals, Inc. | | | Concert Pharmaceuticals, Inc. | | | Otonomy, Inc. | |
| Alimera Sciences, Inc | | | Corbus Pharmaceuticals, Inc. | | | Ovid Therapeutics Inc. | |
| Ardelyx, Inc | | | Cymabay Therapeutics | | | Rigel Pharmaceuticals | |
| Assembly Biosciences, Inc | | | Five Prime Therapeutics | | | Seres Therapeutics, Inc. | |
| Athersys, Inc. | | | Geron Corp. | | | Syros Pharmaceuticals, Inc. | |
| Biocryst Pharmaceuticals, Inc. | | | Glycomimetics, Inc. | | | Trevena | |
| Calithera Biosciences | | | Marinus Pharmaceuticals | | | Ziopharm Oncology, Inc. | |
| Cara Therapeutics, Inc. | | | Medicinova Inc. | | | | |
| Catabasis Pharmaceuticals, Inc. | | | Minerva Neurosciences, Inc. | | | | |
Name
|
| |
Number of Securities
Underlying Unexercised Options (#) (Exercisable) |
| |
Number of
Securities Underlying Unexercised Options (#) (Unexercisable) |
| |
Option
Exercise Price ($) |
| |
Option
Expiration Date |
| ||||||||||||
Armando Anido
|
| | | | 292,553 | | | | | | — | | | | | | 3.98 | | | | | | 10/02/2024 | | |
| | | | | 396,678 | | | | | | — | | | | | | 14.00 | | | | | | 08/04/2025 | | |
| | | | | 117,188 | | | | | | 7,812(1) | | | | | | 18.22 | | | | | | 01/25/2027 | | |
| | | | | 55,688 | | | | | | 25,312(2) | | | | | | 11.71 | | | | | | 01/11/2028 | | |
| | | | | 70,000 | | | | | | 90,000(3) | | | | | | 3.65 | | | | | | 01/24/2029 | | |
| | | | | | | | | | | 162,480(4) | | | | | | 5.05 | | | | | | 01/30/2030 | | |
Terri B. Sebree
|
| | | | 146,276 | | | | | | — | | | | | | 3.98 | | | | | | 10/02/2024 | | |
| | | | | 201,981 | | | | | | — | | | | | | 14.00 | | | | | | 08/04/2025 | | |
| | | | | 70,313 | | | | | | 4,687(1) | | | | | | 18.22 | | | | | | 01/25/2027 | | |
| | | | | 30,195 | | | | | | 13,725(2) | | | | | | 11.71 | | | | | | 01/11/2028 | | |
| | | | | 52,500 | | | | | | 67,500(3) | | | | | | 3.65 | | | | | | 01/24/2029 | | |
| | | | | | | | | | | 120,000(4) | | | | | | 5.05 | | | | | | 01/30/2030 | | |
James E. Fickenscher
|
| | | | 150,000 | | | | | | — | | | | | | 10.23 | | | | | | 09/13/2026 | | |
| | | | | 29,391 | | | | | | 1,959(1) | | | | | | 18.22 | | | | | | 01/25/2027 | | |
| | | | | 46,406 | | | | | | 21,094(2) | | | | | | 11.71 | | | | | | 01/11/2028 | | |
| | | | | 38,543 | | | | | | 49,556(3) | | | | | | 3.65 | | | | | | 01/24/2029 | | |
| | | | | | | | | | | 85,000(4) | | | | | | 5.05 | | | | | | 01/30/2030 | | |
Name of Beneficial Owner
|
| |
Amount and
Nature of Beneficial Ownership(1) |
| |
Percent of
Class |
| ||||||
Directors and Executive Officers: | | | | | | | | | | | | | |
Armando Anido(2)
|
| | | | 1,629,045 | | | | | | 3.85% | | |
Terri B. Sebree(3)
|
| | | | 900,088 | | | | | | 2.15% | | |
James E. Fickenscher(4)
|
| | | | 437,031 | | | | | | 1.05% | | |
John P. Butler(5)
|
| | | | 70,000 | | | | | | * | | |
Warren D. Cooper, MB, BS, BSc, MFPM(6)
|
| | | | 95,000 | | | | | | * | | |
William J. Federici(7)
|
| | | | 102,865 | | | | | | * | | |
Daniel L. Kisner, MD(8)
|
| | | | 95,000 | | | | | | * | | |
Kenneth I. Moch(9)
|
| | | | 107,055 | | | | | | * | | |
Pamela Stephenson(10)
|
| | | | 38,333 | | | | | | * | | |
All directors, director nominees and executive officers as a group (11 persons)(11)
|
| | | | 4,008,867 | | | | | | 9.11% | | |
5% or more Stockholders (none) | | | | | | | | | | | | | |
| | |
2020
|
| |
2019
|
| ||||||
Audit Fees
|
| | | $ | 403,500 | | | | | $ | 387,000 | | |
Audit-related Fees
|
| | | | — | | | | | | — | | |
Tax Fees
|
| | | | — | | | | | | — | | |
All Other Fees
|
| | | | 1,780 | | | | | | 1,780 | | |
Total
|
| | | $ | 405,280 | | | | | $ | 388,780 | | |
| | | |
By:
|
|
| | | |
Name:
Title: |
|
1 Year Zynerba Pharmaceuticals Chart |
1 Month Zynerba Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions